1 / 0

Meda Biotech LLc .

Meda Biotech LLc . GOAL IS TO ESTABLISH AN AMERICAN COMPANY TO SUPPORT THE HEALTH COMMUNITY WITH THERAPEUTICS, DIAGNOSTICS AND LIFE STYLE DRUGS (NATURAL INTACT MOLECULES USING MODERN SCIENCE)

eytan
Télécharger la présentation

Meda Biotech LLc .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Meda Biotech LLc.

    GOAL IS TO ESTABLISH AN AMERICAN COMPANY TO SUPPORT THE HEALTH COMMUNITY WITH THERAPEUTICS, DIAGNOSTICS AND LIFE STYLE DRUGS (NATURAL INTACT MOLECULES USING MODERN SCIENCE) *We are focused to support our innovation and discoveries by selling diagnostic kits and life style drugs * At this point our next stage which is clinical trials for Hybrid Paclitaxel and marketing of life style drugs require more funds
  2. STRENGTH AT PRESENT INNOVATIVE SCIENCE AND SCIENTISTS DIAGNOSTICS TEST KITS TO GENERATE SOME REVENUE LIEF STYLE DRUGS FROM NATURAL MOLECULES READY FOR MARKETING IN FACT ALREADY IN MARKET AND HAVE STARTED GENERATING SOME REVENUE TO PAY OUR RENT. GREAT ACCEPTABILITY WITH 100% +VE FEED BACK A PATENTED DISCOVERY TO DEVELOP HYBRID DRUGS WE FOCUS ON PACLITAXEL ( NEED NOT TO DESCRIBE A GOLDEN BULLET FOR CANCER SO FAR) IS READY FOR CLINICAL TRILAS. I WILL DISCUSS MORE DETAILS IN NEXT SLIDES
  3. MewTaxel

    DISCOVERY OF HYBRID DRUGS

    Potent, Safe and Patented A MOLECULE= NON SOLUBLE IN WATER B MOLECULE= NON SOLUBLE IN WATER C MOLECULE = SOLUBLE IN WATER A+B = NON SOLUBLE IN WATER A+C = NON SOLUBLE IN WATER A+B+C = IS SOLUBLE IN WATER WHICH IS AN INNOVATION OR DISCOVERY AND IS THE NEED OF THE DRUG. THE DISCOVERY DOES NOT ALTER ANY OF THE MOLECULE PARTNER IN THIS HYBRID.
  4. MewTaxel

    PACLITAXELHYBRID

    MewTaxel HYBRID CPT251(MewTaxel) A NEW TREATMENT FOR CANCER SAFE AND MORE EFFECTIVE CHEMOTHERAPY Dr.Mewa Singh 609-902-7128 mewasinghsandhu@hotmail.com www.nanosgroup.com/ Meda Biotech , USA
  5. RATIONAL MewTaxel $5B MARKET FREE FROM PATENT CAPTURE THE MARKET WITH NEW PATENT PROTECTION EITHER BY IMPROVEMENT EITHER BY CHANGING THE MOLECULE EITHER BY CONJUGATION OR HYBRIDIZATION DECREASE TOXICITY INCREASE EFFICACY OUR TECHNOLOGY IS SIMPLE (WITHOUT ANY POLYMER CONJUGATION)- HYBRID. MANUFACTURING COST IS LOW COMPANIES HAD AND HAVE INVESTED 100M $ ON THIS. WE JUST GOT THE SAME IN JUST LITTLE OVER 1M$! OFF COURSE WE ARE NOT CALCULATING OUR TIME INVESTMENT.
  6. PROBLEM MewTaxel SOLUBILITY TOXICITY (The castor-oil carrier is suspected as the culprit behind the misery which includes nausea, vomiting, joint pain, appetite loss, brittle hair and tingling sensations in hands and feet (neuropathy). DRUG RESISTANCE MANUFACTURING AND ADMINISTING COST AT CLINIC PATENT PROTECTION (Expired) THREAT OF GENERIC TO EXISTING ESTABLISHED MARKET HIGH PRODUCTION AND ADMINISTRATION ON SITE COST
  7. IMPROVEDANDNEWMewTaxel MewTaxel WATER SOLUBLE HYBRID, DOUBLE EDGE FORMULATION LESS TOXIC HIGH POTENCY LOW MANUFACTURING AND ADMINISTRATION COST AT CLINIC NO CHANGE IN INTEGRITY OF THE MOLECULES PATENT FILED FOR NEW INVENTION FOR HYBRID. NO CASTOR OIL, NO ALCOHOL, NO DETERGENT, NO PROTEIN, NO CHEMISTRY CHANGE ON TOP OF THAT IT IS MORE POTENT, LESS TOXIC AND LESS MANUFACTURING COST. NO COMPLEX CONJUGATION STEP LOW MANUFACTURING COST AND SIMPLE AT DRs. SITE
  8. PROGRESS MewTaxel PROOF OF CONCEPT -------------ESTABLISHED R & D---------------------------------ESTABLISHED PILOT SCALE MANUFACTURING---ESTABLISHED IN-VITRO STUDY-------------------PRELIMINARY TESTING ESTABLISHED ANIMAL STUDIES-------------- ON-GOING
  9. FUNDS MewTaxel $1M INVESTED $3M NEEDED ( ANALYTICAL TOOL, CGMP MANUFACTURING, PRE-CLINICAL, IND, CLINICAL) $1M WILL BE INVESTED FOR MANUFACTURING AND MARKETING OF OUR DIAGNOSTIC KITS AND LIFE STYLE DRUGS $2M WILL BE FOR cGMP, QC, PRECLINICALS AND PHASE-I CLINICALS
  10. MILESTONES MewTaxel Scale Manufacturing (2012) Animal efficacy: Drug Interactions (2013) IND (2014) Phase I (2015) Phase II (2016-17) License submission (2017-18)
  11. POTENCY MewTaxel MewTaxelis Potent at 1.1 nM ( ic50 is 30nM) MewTaxelis potent at 5nm ( ic50 is >60nM) Much lower than taxol
  12. SAFEANDPOTENTTHE MEWTAXEL MewTaxel Paclitaxel in water MewTaxel in water Solubility NO CASTOR OIL, NO ALCOHOL, NO DETERGENT, NO PROTEIN, NO CHEMISTRY CHANGE ON TOP OF THAT IT IS MORE POTENT, LESS TOXIC AND COST EFFECTIVE. Act on multiple site MewTaxel
  13. SYNERGISTIC/POTENTIATING TAxolMewsuppresses production ofproteins needed for uncontrolled growthand proliferation, inflammation and inhibitionof PGE-2. TAxolMewinactivates NF-kappa B, genes involved in cell proliferation, such as COX-2, cyclin D1, and c-myc. TaxolMew also helps to restore normal programmed cell death. In a study, taxol induced NF-kappa B activation led to cell immortality, reducing the drug's ability to kill cancer cells. Drug resistance is a huge problem. But TAxolMew can help to make chemotherapeutic agents more effective. INNOVATIVE: Hybrid Partner Arrested stem cell development.TaxolMew inhibits growth and renewal of so-called cancer stem cells, aberrant cells now believed to be at the root of many cancers, including breast cancer. Mitotic arrest-Taxol TaxolMewinhibited taxol's inflammatory response by blocking nuclear factor-kappa B (NF-kappa B) which regulates inflammation, cell proliferation, and apoptosis (cell death).
  14. LASTBUSINESSDEAL ( VALUE) MewTaxel Now that Celgene has wrapped up its $3 billion-plus buyout of AbraxisBioScience, analysts are cheering. That wasn't necessarily the case in June, when the companies announced their deal--and investors responded by selling off their stock, sending the price plummeting to $48. But as Investor's Business Daily reports, Celgene shares are now trading at near $60, and observers think the combo will eventually transform the company into a "biopharmaceutical giant."Read more: Abraxis deal done, Celgene eyes cancer franchise - FiercePharmahttp://www.fiercepharma.com/story/abaxis-deal-done-celgene-eyes-cancer-franchise/2010-10-25#ixzz1ibPApSSD We took even albumin out and made it soluble Hybrid MewTaxel should has a better deal
  15. MARKET OVERVIEW EXISTING MARKET IS $5BILLION SINCE IT IS IN CLINICAL TRIAL WITH MANY COMBINATION WITH BIOLOGICS AND MANY OTHER CANCER TREATMENTS, IT WILL GROW IN FUTURE WE ARE VERY DIFFERENT THAN ANY OTHER FORMULATION , SO AFTER CLINICAL, WE HAVE A BETTER POSITION IN MARKET NOT A ME-TOO CONCEPT BUT DISTINGUISH YOURSELF AWAY FROM COMPETITION
  16. COMPETITION Abbott Laboratories, Aphios Corporation, Angiotech, Inc., British Technology Group, Cell Therapeutics, Inc., Dabur India Ltd.Enzon, Inc., F.H. Faulding & Co. Ltd., Guilford Pharmaceuticals, Inc., Hauser, Inc., IVAX Corp., LDS Technologies, Inc., MacroMed, Inc., Matrix Pharmaceuticals, Inc., Mylan Laboratories, Inc.NaProBioTherapeutics, Inc., Natural Pharmaceuticals, Inc., Natland International CorporationNeoPharm, Inc., Novopharm Biotech, Inc., Novopharm Ltd., N.V. Boehringer-Ingelheim SAPharmacia & Upjohn Co., Phytogen Life Sciences, Inc., PhytonCatalytica, Protarga, Inc., SamyangGenex Corp., Schein Pharmaceuticals, Inc.Sonus Pharmaceuticals, Inc., STS Particles, Inc./MedisperseSupergen, Inc., Taxalog, Inc., Teva Pharmaceutical Industries, Ltd.The Liposome Company, VivoRx Pharmaceuticals, Inc. NON OF THEM ARE WITH HYBRID TECHNOLOGY
  17. GO-TO-MARKET STRATEGY BEST IS TO JOIN WITH BIG PHARMA BUT IF FUNDED OR GENERATE ENOUGH REVENUE FROM OUR OTHER PRODUCTS TO SUPPORT ALL CLINICAL TRIALS, A BETTER VALUE CAN BE BUILD UP FOR THE COMPANY
  18. MANAGEMENT OVERVIEW Mewa Singh. PhD : Inventor, investor and COO. More than 20 years of experience in Diagnostics, Vaccine , therapeutics. He has delivered more than 30 products. All are in the market. He has experience to take the product from concept to market. ManinderSandhu, MA Economics: She has been managing the financial , accounts and day to day management of the company here in USA and India. JagjitSaluja, BSc : Creating sale in India for diagnostic kits and catering day to day material for company
  19. ADVISORY BOARD Arthur R. Cooper Arthur Cooper serves as CEO of the LSU System Research and Technology Foundation with a focus on helping Louisiana Universities commercialize their technology. He also is the Executive Director of the Louisiana Emerging Technology Center and is responsible for operation of the Baton Rouge Life Science incubator. He previously served as director of Business, Retention and Assistance Services for the Louisiana Department of Economic Development and as such he worked closely with the Small Business Development Centers, local chambers of commerce, micro enterprise development centers, and local economic developers. Arthur is a Baton Rouge native with 16 years experience in the practice of law, with extensive work in intellectual property issues. He was a design engineer, CEO of a startup biotech food company and a managing partner of a law firm. He has a B.S. in Electrical Engineering from Louisiana State University and a J.D. (Juris Doctor) from Louisiana State University Law Center.
  20. ADVISORY BOARD K. Gus Kousoulas, PhD : Affiliate Member, Stanley S. Scott Cancer Center, LSUHSC, New Orleans Director, Division of Biotechnology & Molecular Medicine (BIOMMED) Director, LSU-Tulane Center for Experimental Infectious Disease Research School of Vet. Med. Bldg. Room 3110 Skip Bertman Drive Baton Rouge, LA 70803 Phone: 225-578-9682 Fax: 225-578-9655 email: vtgusk@lsu.edu
  21. ADVISORY BOARD Dr. Anil Kumar ChawlaScientist Quality, Safety and Standards Department of Immunization Vaccines and BiologicalsWorld Health Organization Geneva, Switzerland Tel. + 41 22 791 5566Fax. + 41 22 791 4384email. chawlaa@who.int
  22. ADVISORY BOARD Dr. Manjit Singh MS ( Therapeutic Oncology) Clinical trial Professor at Medical College, Amritsar, India Need to have Regulatory and Financial Advisor in Board of Management
  23. Successfully improved Hybrid drugs for solubility
  24. Other Products ready to market with cutting edge technology MARKET OVERVIEW Probiotic-----------------------$100M UTI -----------------------------$371M For joints health-------------$9B CurcuTea--------------------- $6.5 billion year 2011 For Alzheimer's------------- $1.2 billion last year Sports Stamina Drink----- $2 billion GERD (Acid Reflux)------$11.7B
  25. Diagnostic Test Kits ( Export Only) HIV1/2 HCV HepB T.B Malaria Dengue Chikungunya PSA
  26. OVERALL OPERATION1st round PHASE-1 : Scale cGMP Manufacturing for all product segments PHASE-2 : Animal efficacy: Drug Interactions for Mewtaxel and marketing of other ready products. PHASE-3 : IND and Phase1 clinical trials.Continue improving the sale of our products and profit stratigy Next round of management discussion
  27. QA THANK YOU ALL
More Related